(NASDAQ: ADAG) Adagene's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.69%.
Adagene's earnings in 2026 is -$17,609,413.On average, 8 Wall Street analysts forecast ADAG's earnings for 2026 to be -$29,450,147, with the lowest ADAG earnings forecast at -$41,213,621, and the highest ADAG earnings forecast at -$22,389,693. On average, 7 Wall Street analysts forecast ADAG's earnings for 2027 to be -$28,999,984, with the lowest ADAG earnings forecast at -$30,184,624, and the highest ADAG earnings forecast at -$27,365,181.
In 2028, ADAG is forecast to generate -$36,652,757 in earnings, with the lowest earnings forecast at -$42,955,041 and the highest earnings forecast at -$27,987,117.